Metastatic malignant melanoma in a patient taking interleukin-1 receptor antagonist.
Daniel
D
Wendling
François
F
Aubin
D000368:Aged; D000962:Antimalarials / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D004359:Drug Therapy, Combination; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000139:chemically induced / Q000473:pathology / Q000556:secondary; D011241:Prednisone / Q000627:therapeutic use; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D012795:Sialoglycoproteins / Q000009:adverse effects* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology
D000962:Antimalarials; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D017472:Receptors, Interleukin-1; D012795:Sialoglycoproteins; D011241:Prednisone